Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

Nvidia’s historic $4 trillion market cap highlights AI chip sector’s central role in tech supremacy, says GlobalData

Nvidia briefly became the first publicly traded company in history to reach a market capitalization of $4 trillion yesterday, outpacing tech giants Apple and Microsoft, and marking a pivotal moment in the global AI landscape. This milestone underscores Wall Street’s accelerating confidence in artificial intelligence (AI) and the central role of high-performance semiconductors, according to […]
Read more

Eli Lilly’s orforglipron and other key catalysts set to reshape drug landscape in Q3 2025, says GlobalData

Eli Lilly and Co’s orforglipron is emerging as a promising oral glucagon-like peptide (GLP)-1 therapy, with upcoming clinical milestones in obesity and diabetes set to shape its market trajectory. As a wave of key catalysts—including FDA decisions and late-stage trial results—approaches in Q3 2025, the pharmaceutical landscape is poised for shifts driven by innovation, competitive […]
Read more

Transcatheter mitral valve repair market in India to grow at 17% CAGR through 2036, forecasts GlobalData

Transcatheter mitral valve repair (TMVR) is among a rising class of catheter-based therapies for heart defects and valve disorders, providing a critical treatment option for patients with severe mitral regurgitation associated with obesity, hypertension, and type 2 diabetes who are not suitable candidates for surgery. The TMVR market in India is projected to grow at […]
Read more

GlobalData acquires Stylus to boost position as leading consumer trends and insights business

GlobalData, a leading data, insight, and technology company, has announced its acquisition of Stylus, the global trend forecaster, to bolster its consumer innovation intelligence offering and increase its ability to help brands create products, predict change, and make more informed business decisions. Founded in 2009 on a foundation of cross-industry trend forecasting and innovation strategy, […]
Read more

Global top 20 insurers report 6.8% YoY average premium growth in 2024, reveals GlobalData

The global top 20 publicly listed insurance companies continued to demonstrate robust momentum in 2024, largely fuelled by a higher interest rate environment and significant investment gains resulting from favorable developments in equity markets. This was further supported by the ongoing digital transformation initiatives, strategic expansion into underpenetrated markets, and effective vertical integration strategies. Consequently, […]
Read more

Iran-Israel war casts long shadow over global markets as strategic uncertainty persists, says GlobalData

The Iran-Israel war casts a long shadow over global markets, with the ceasefire offering only a temporary pause in hostilities rather than a path to resolution. Strategic uncertainty continues to loom large, raising critical questions about the motivations behind Israel’s military actions and the future of Iran-Israel relations. From disrupted oil flows and rising inflation […]
Read more

Card payments market in Japan to surpass $890 billion in 2025 as cashless shift gains momentum, forecasts GlobalData

Japan’s card payment market is set to grow 9.6% in 2025f to reach JPY134.9 trillion ($892.5 billion), driven by rising consumer spending and a shift toward digital payments. While cash remains dominant, strong government support, growing card penetration, and evolving consumer preferences are accelerating Japan’s transition to a more cashless economy, reshaping the financial services […]
Read more

Big Pharma prepare for next patent cliff as blockbuster drugs revenue losses loom, says GlobalData

The pharmaceutical industry is bracing for one of its most financially significant patent cliffs in over a decade, with multiple blockbuster drugs set to lose exclusivity by 2030. As biosimilars and generics flood the market, pricing pressures will intensify—particularly in oncology—challenging pharma companies to rethink revenue strategies, pipeline investments, and lifecycle management to safeguard long-term […]
Read more

Lineage Cell Therapeutics’ OpRegen holds potential to become new treatment option for GA, says GlobalData

Lineage Cell Therapeutics’ OpRegen (RG6501) is gaining attention as a promising one-time allogenic cell therapy for geographic atrophy (GA), following encouraging results from its Phase I/IIa trial. With limited treatment options currently available, OpRegen’s ability to improve and stabilize vision positions it as a potential breakthrough in addressing a critical unmet need in GA management, […]
Read more

High costs and limited access threaten progress in HIV treatment despite new drug advances, says GlobalData

Despite major strides in antiretroviral therapy (ART), the human immunodeficiency virus (HIV) market still faces serious challenges that threaten long-term control of the disease. The most pressing issue is the lack of affordable access to newer therapies, which—despite offering better adherence and fewer side effects—remain out of reach for many patients due to high costs […]
Read more

New CGM-enabled insulin delivery systems address demand for automated diabetes care, says GlobalData

With around 2 million Americans living with type 1 diabetes, and an increasing number of insulin-requiring type 2 cases, the US healthcare system is experiencing growing demand for simplified, automated diabetes care. The integration of Abbott Laboratories’ FreeStyle Libre 3 Plus continuous glucose monitor (CGM) with the Tandem t:slim X2 insulin pump system marks a […]
Read more
1 … 27 28 29 30 31 … 209